Abstract
Objective To examine whether regions participating in the NHS-Galleri trial of a multi-cancer early detection test experienced changes in cancer diagnostic delay rates that could indicate the presence of spillover due to constraints on care delivery.
Design Quasi-experimental difference-in-differences analysis.
Setting NHS England, April 2021-September 2023.
Participants All 21 cancer alliance regions in NHS England, 8 of which participated in the trial and 13 of which did not.
Main outcomes Rates of cancer diagnostic delays, defined as the percentage of patient referrals for investigation of possible cancer that resulted in diagnostic resolution within 28 days of initial referral. A difference-in-differences analysis was used to compare diagnostic delay rates in regions that participated in the NHS-Galleri trial to regions that did not participate, before and after the start of the trial. Three primary analyses were conducted: for all types of suspected cancer; for the most commonly referred cancers (breast, skin, lower gastrointestinal); and for less commonly referred cancers (all other types).
Results We observed no significant differences in rates of diagnostic delay for all cancers or for the most commonly referred cancers. For less commonly referred cancers, the percentage of patients experiencing diagnostic delays increased from 32.6% to 35.1% in regions participating in the NHS-Galleri trial from the 6 months before to the 6 months after trial start, compared with a small reduction from 32.7% to 31.7% in regions that did not participate (adjusted difference 3.4 percentage points, 95% confidence interval 1.2 to 5.7). These differences persisted from 6 to 12 months after trial start and receded the following year.
Conclusions Regional participation in the NHS-Galleri trial was associated with a statistically significant increase in diagnostic delay rates for less commonly referred cancers in the first year of the trial, but not for cancer overall or the most commonly referred cancers. Rollout of the trial intervention may have increased demand for downstream diagnostic services and, in a capacity constrained environment, led to region-wide increases in delayed diagnosis for less commonly referred cancers. If patients in the control group faced delayed diagnosis as a result, this would represent spillover due to constraints on care delivery during the first year and could affect measurement of the trial’s primary outcome, incidence of later stage cancer at time of diagnosis. This study underscores the importance of addressing spillover in clinical trials of interventions that affect availability of healthcare services.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/disclosure-of-interest/ and declare: all authors are employed by RAND, which provided support for this work. SM has received research funding from the Patient-Centered Outcomes Research Institute and Centers for Medicare & Medicaid Services. BAG has received research funding and honoraria from the National Institutes of Health and received support for travel to a meeting from Syracuse University. Authors had no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
This study did not receive any external funding. This work was supported by RAND, which employs the authors. RAND had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The funders had no role in considering the study design or in the collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability statement
Data are available in a public, open access repository. The data used in this study are aggregated monthly provider cancer waiting times statistics which are freely available to download from the following website: https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/monthly-prov-cwt/
